Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pancreatic Cancer Metastatic × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 204 Breast Neoplasms 166 Ovarian Neoplasms 96 Neoplasms 92 Neoplasm Metastasis 51 Lung Neoplasms 46 Fallopian Tube Neoplasms 41 Triple Negative Breast Neoplasms 37 Parkinson Disease 4, Autosomal Dominant Lewy Body 36 Stomach Neoplasms 35 Endometrial Neoplasms 30 Carcinoma, Ovarian Epithelial 29 Squamous Cell Carcinoma of Head and Neck 27 Uterine Cervical Neoplasms 20 Carcinoma 20 Recurrence 19 Esophageal Neoplasms 19 Colorectal Neoplasms 19 Pancreatic Neoplasms 15 Melanoma 15 Head and Neck Neoplasms 14 Esophageal Squamous Cell Carcinoma 14 Small Cell Lung Carcinoma 12 Solid Tumors 11 Carcinoma, Renal Cell 10 Adenocarcinoma 10 Urinary Bladder Neoplasms 9 Advanced Solid Tumors 9 Solid Tumor 8 Carcinoma, Squamous Cell 8

Interventions

folfirinox 1 devimistat 1 Paclitaxel 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Injections 1 Gemcitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06752811 2026-02-10

pompom

Shanghai Yizhong Pharmaceutical Co., Ltd.

Phase 3 Recruiting

Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡